Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

1.37
+0.12009.60%
Post-market: 1.380.0100+0.73%19:21 EDT
Volume:3.67M
Turnover:4.98M
Market Cap:157.00M
PE:-0.84
High:1.42
Open:1.26
Low:1.26
Close:1.25
Loading ...

Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits

MT Newswires Live
·
10 Dec 2024

BRIEF-Fate Therapeutics Presents New Phase 1 Clinical Data Of Ft819 Off-The-Shelf

Reuters
·
10 Dec 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 off-the-Shelf, Car T-Cell Product Candidate for Systemic Lupus Erythematosus

THOMSON REUTERS
·
10 Dec 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

GlobeNewswire
·
10 Dec 2024

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Veeva Systems (VEEV) and Alcon (ALC)

TIPRANKS
·
06 Dec 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Dec 2024

Fate Therapeutics Announces Leadership Transition for 2025

TIPRANKS
·
30 Nov 2024

Fate Therapeutics Taps Bob Valamehr to Be CEO

Dow Jones
·
30 Nov 2024

BRIEF-Fate Therapeutics Says Bob Valamehr To Become President, CEO As Of Jan 2025

Reuters
·
30 Nov 2024

Fate Therapeutics CEO Wolchko to retire

TIPRANKS
·
30 Nov 2024

Fate Therapeutics Inc - Scott Wolchko to Continue as Strategic Advisor

THOMSON REUTERS
·
30 Nov 2024

Fate Therapeutics Inc - Bob Valamehr to Become President and CEO Jan 1, 2025

THOMSON REUTERS
·
30 Nov 2024

Fate Therapeutics Announces Leadership Transition

THOMSON REUTERS
·
30 Nov 2024

Press Release: Fate Therapeutics Announces Leadership Transition

Dow Jones
·
30 Nov 2024

Fate Therapeutics to Present at Upcoming December Investor Conferences

GlobeNewswire
·
27 Nov 2024

Positive Clinical Developments and Promising Outcomes Propel Fate Therapeutics’ Growth Potential

TIPRANKS
·
21 Nov 2024

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Zacks
·
20 Nov 2024

BofA Securities Upgrades Fate Therapeutics to Neutral From Underperform, $3 Price Target

MT Newswires Live
·
19 Nov 2024

Barclays Releases a Buy Rating on Fate Therapeutics (FATE)

TIPRANKS
·
19 Nov 2024

Fate upgraded to Neutral at BofA after FT819 achieves DORIS remission

TIPRANKS
·
19 Nov 2024